Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Jódar, Esteban; Michelsen, Marie; Polonsky, William; Réa, Rosangela; Sandberg, Anna; Vilsbøll, Tina; Warren, Mark; Harring, Signe; Ziegler, Uwe; Bain, Steve

doi:10.1111/dom.14039

Journal article 340 views 106 downloads

Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Esteban Jódar, Marie Michelsen, William Polonsky, Rosangela Réa, Anna Sandberg, Tina Vilsbøll, Mark Warren, Signe Harring, Uwe Ziegler, Steve Bain

Diabetes, Obesity and Metabolism

Swansea University Author: Steve Bain

PDF | Version of Record

Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC).
Download (1.08MB)

Check full text

DOI (Published version): 10.1111/dom.14039

Published in:	Diabetes, Obesity and Metabolism
ISSN:	1462-8902 1463-1326
Published:	Wiley 2020
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa54313
Tags:	Add Tag No Tags, Be the first to tag this record!

first_indexed	2020-05-26T19:08:07Z
last_indexed	2023-01-11T14:32:18Z
id	cronfa54313
recordtype	SURis
fullrecord	<?xml version="1.0"?><rfc1807><datestamp>2022-12-02T18:46:38.1674795</datestamp><bib-version>v2</bib-version><id>54313</id><entry>2020-05-26</entry><title>Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-05-26</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>Diabetes, Obesity and Metabolism</journal><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1462-8902</issnPrint><issnElectronic>1463-1326</issnElectronic><keywords>cardiovascular disease, GLP-1 analogue, hypoglycaemia, incretin therapy, type 2 diabetes,weight control</keywords><publishedDay>27</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-04-27</publishedDate><doi>10.1111/dom.14039</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T18:46:38.1674795</lastEdited><Created>2020-05-26T14:46:57.1998475</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Esteban</firstname><surname>Jódar</surname><order>1</order></author><author><firstname>Marie</firstname><surname>Michelsen</surname><order>2</order></author><author><firstname>William</firstname><surname>Polonsky</surname><order>3</order></author><author><firstname>Rosangela</firstname><surname>Réa</surname><order>4</order></author><author><firstname>Anna</firstname><surname>Sandberg</surname><order>5</order></author><author><firstname>Tina</firstname><surname>Vilsbøll</surname><order>6</order></author><author><firstname>Mark</firstname><surname>Warren</surname><order>7</order></author><author><firstname>Signe</firstname><surname>Harring</surname><order>8</order></author><author><firstname>Uwe</firstname><surname>Ziegler</surname><order>9</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>10</order></author></authors><documents><document><filename>54313__17521__c4d84b994aef4a59a538ada19d7158e8.pdf</filename><originalFilename>54313VOR.pdf</originalFilename><uploaded>2020-06-18T10:09:08.8822732</uploaded><type>Output</type><contentLength>1130633</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling	2022-12-02T18:46:38.1674795 v2 54313 2020-05-26 Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6) 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2020-05-26 BMS Journal Article Diabetes, Obesity and Metabolism Wiley 1462-8902 1463-1326 cardiovascular disease, GLP-1 analogue, hypoglycaemia, incretin therapy, type 2 diabetes,weight control 27 4 2020 2020-04-27 10.1111/dom.14039 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2022-12-02T18:46:38.1674795 2020-05-26T14:46:57.1998475 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Esteban Jódar 1 Marie Michelsen 2 William Polonsky 3 Rosangela Réa 4 Anna Sandberg 5 Tina Vilsbøll 6 Mark Warren 7 Signe Harring 8 Uwe Ziegler 9 Steve Bain 0000-0001-8519-4964 10 54313__17521__c4d84b994aef4a59a538ada19d7158e8.pdf 54313VOR.pdf 2020-06-18T10:09:08.8822732 Output 1130633 application/pdf Version of Record true Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC). true eng http://creativecommons.org/licenses/by-nc/4.0/
title	Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
spellingShingle	Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6) Steve Bain
title_short	Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
title_full	Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
title_fullStr	Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
title_full_unstemmed	Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
title_sort	Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
author_id_str_mv	5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv	5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author	Steve Bain
author2	Esteban Jódar Marie Michelsen William Polonsky Rosangela Réa Anna Sandberg Tina Vilsbøll Mark Warren Signe Harring Uwe Ziegler Steve Bain
format	Journal article
container_title	Diabetes, Obesity and Metabolism
publishDate	2020
institution	Swansea University
issn	1462-8902 1463-1326
doi_str_mv	10.1111/dom.14039
publisher	Wiley
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str	1
active_str	0
published_date	2020-04-27T04:07:46Z
_version_	1763753556042579968
score	10.970702

Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Similar Items